Abstract: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Irreversible airflow limitation, both progressive and associated with an inflammatory response of the lungs to noxious particles or gases, is a hallmark of the disease. Cigarette smoking is the most important environmental risk factor for COPD, nevertheless, only approximately 20-30% of smokers develop symptomatic disease. Epidemiological studies, case-control studies in relatives of patients with COPD, and twin studies suggest that COPD is a genetically complex disease with environmental factors and many involved genes interacting together. Two major strategies have been employed to identify the genes and the polymorphisms that likely contribute to the development of complex diseases: association studies and linkage analyses. Biologically plausible pathogenetic mechanisms are prerequisites to focus the search for genes of known function in association studies. Protease-antiprotease imbalance, generation of oxidative stress, and chronic inflammation are recognized as the principal mechanisms leading to irreversible airflow obstruction and parenchymal destruction in the lung. Therefore, genes which have been implicated in the pathogenesis of COPD are involved in antiproteolysis, antioxidant barrier and metabolism of xenobiotic substances, inflammatory response to cigarette smoke, airway hyperresponsiveness, and pulmonary vascular remodelling. Significant associations with COPD-related phenotypes have been reported for polymorphisms in genes coding for matrix metalloproteinases, microsomal epoxide hydrolase, glutathione-S-transferases, heme oxygenase, tumor necrosis factor, interleukines 1, 8, and 13, vitamin D-binding protein and β-2-adrenergic receptor (ADRB2), whereas adequately powered replication studies failed to confirm most of the previously observed associations. Genome-wide linkage analyses provide us with a novel tool to identify the general locations of COPD susceptibility genes, and should be followed by association analyses of positional candidate genes from COPD pathophysiology, positional candidate genes selected from gene expression studies, or dense single nucleotide polymorphism panels across regions of linkage. Haplotype analyses of genes with multiple polymorphic sites in linkage disequilibrium, such as the ADRB2 gene, provide another promising field that has yet to be explored in patients with COPD. In the present article we review the current knowledge about gene polymorphisms that have been recently linked to the risk of developing COPD and/or may account for variations in the disease course.
Introduction
Airflow limitation that is usually progressive, not fully reversible, and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, is a hallmark of chronic obstructive pulmonary disease (COPD) (Celli et al. 2004) . Typical findings in patients with COPD include chronic bronchitis with mucus hypersecretion, small airway disease (bronchiolitis), emphysema and pathological pulmonary vascular changes, the degree of each may vary substantially between different patients (Celli et al. 2004) . Although COPD affects the lungs, it also produces significant systemic consequences characterized by the presence of inflammatory response in the systemic compartment (Wouters 2005) . COPD is the fourth-leading cause of death in Western countries, and a substantial and increasing economic and social burden results from the Gene polymorphisms in COPD 21 disease worldwide (Celli et al. 2004) . Importantly, more than a third of COPD patients will develop hypoxiaassociated pulmonary hypertension in the course of their disease, and they will experience a further increase in morbidity and mortality as a result (Barbera et al. 2003) .
Cigarette smoking is the most important environmental risk factor for the development of COPD (Sandford & Silverman 2002; Celli et al. 2004 ). Nevertheless, despite its recognized importance only 20-30% of smokers develop symptomatic COPD (Lokke et al. 2006) . Moreover, the extent of cigarette smoking, i.e. packyears and duration of smoking, account for only about 15% of the variation in lung function decline in smokers (Beck et al. 1981) . Epidemiological studies, case-control studies in relatives of patients with COPD, and twin studies indicate that COPD is a genetically complex disease with environmental factors and many involved genes interacting together (Silverman et al. 1998; Sandford & Silverman 2002) . Such interactions are defined by a non-additive contribution of each gene and environmental factor to the overall phenotype, thus confering a different level of risk than expected by simply adding them (Sandford & Silverman 2002) .
Proteinase-antiproteinase imbalance, generation of oxidative stress, and chronic inflammation are recognized as the principal mechanisms leading to irreversible airflow obstruction and parenchymal destruction in the lung, resulting in emphysema (Celli et al. 2004) . Therefore, the genes that have been implicated in the pathogenesis of COPD are involved in antiproteolysis, metabolism of xenobiotic compounds, antioxidant barrier, inflammatory response to xenobiotic substances in cigarette smoke, airway hyperresponsiveness, and in the development of pulmonary vascular disease.
Severe α 1 -antitrypsin deficiency with a simple Mendelian inheritance and related more common genetic variants of this serine protease-inhibitor that confer the susceptibility to the disease have been thoroughly reviewed elsewhere (Joos et al. 2002b; Sandford & Silverman 2002) . In this review we attempt to summarize the up-to-date knowledge about other gene polymorphisms that have been linked to the risk of developing COPD and/or may account for variations in the disease course. These occur in genes coding for matrix proteinases/inhibitors, enzymes involved in the metabolism of xenobiotic substances, inflammatory mediators, receptors that mediate bronchial hyperresponsiveness, and a separate section deals with the genetics of COPD-associated pulmonary hypertension.
Approaches to the identification of COPD susceptibility genes
Results of segregation analyses (Chen et al. 1996; Givelber et al., 1998) and epidemiological studies (Silverman et al. 1998 ) suggested polygenic inheritance of COPD, with the genetic component consisting of several genes of a small effect each, rather than of single major gene. The science of genetics largely depends on the study of variations (polymorphisms), and a molecular geneticist tries to identify a polymorphism in DNA that results in an altered phenotype (e.g. the presence of COPD) in particular environmental circumstances (e.g. smoking). Two major strategies have been employed to identify the genes and the polymorphisms that are likely to contribute to the development of complex diseases including COPD: association studies and linkage analyses (Cookson 2006) .
In the candidate gene-association approach the polymorphisms in individual genes thought to be important in the disease pathogenesis are tested for their involvement in the given disease. The aim of this approach is to identify candidate genes and gene polymorphisms that might be functionally relevant. The advantages of association studies are as follows: (a) the use of the knowledge of biologically plausible pathogenetic mechanisms to focus the search for genes of known function; and (b) the study subjects are usually unrelated individuals so that genotypic and phenotypic data from multiple generations are not required (Tebbutt et al. 2007) .
The second major gene-hunting strategy, a linkage analysis (sometimes referred to as positional cloning or genomic scanning) is the classical method for randomly searching the entire human genome for disease-causing genes. It determines whether any of DNA markers genotyped in affected families (at least two generations or sibling-pairs of a single generation) are inherited in association with the occurrence of the disease more often than would be predicted by chance (Tebbutt et al. 2007 ). Genome-wide linkage analyses may also be performed to identify the general locations of COPD susceptibility genes, followed by association analyses, with assessment of the following: (i) positional candidate genes from COPD pathophysiology; (ii) positional candidate genes selected from gene expression studies; or (iii) dense single nucleotide polymorphism (SNP) panels across regions of linkage. A rare variant analysis involves systematically searching for all variants in a gene of interest, often followed by functional studies (Silverman 2006) .
Gene polymorphisms of matrix metalloproteinases in COPD
Various proteinases in lung parenchyma break down connective-tissue components, such as elastin by the action of neutrophil-derived elastase, thus resulting in emphysema. This concept explains the mechanism of the development of COPD with predominant emphysematous phenotype in patients with α 1 -antitrypsin deficiency (Sandford et al. 1999) . Nevertheless, the imbalance between proteinases and antiproteinases plays an important pathogenetic role also in patients with normal concentrations of α 1 -antitrypsin. In addition to the degradation of elastic fibres and other components of extracellular matrix, different proteinases may liberate chemotaxins from the extracellular matrix, inhibit removal of apoptotic cells, induce and inactivate (Parks & Shapiro 2001) . Moreover, during the disease state cells within the lung itself are also capable of producing metalloenzymes with proteolytic activity: type II pneumocytes from lungs of patients with emphysema were identified as a site of increased expression of MMP-1 (Imai et al. 2001) . MMPs represent a family of more than 20 proteolytic enzymes, some of which digest collagen whereas others possess elastolytic activity, and thus play an essential role in tissue remodelling and repair associated with development and inflammation (Nagase & Woessner 1999 ). Both animal and human studies were focused on the role of macrophages and macrophagederived proteinases in tobacco smoke-induced lung injury (Hautamaki et al. 1997; Segura-Valdez et al. 2000) . Macrophage metalloelastase (i.e. MMP-12) knock-out mice exposed to cigarette smoke were protected against the development of emphysema (Hautamaki et al. 1997 ). In addition, it was shown that the macrophage metalloelastase acts not only as an elastolytic enzyme in the lung tissue, but also activates TNF-α, a key inflammatory mediator, in response to inhaled cigarettesmoke in rodents (Churg et al. 2003) . In lung tissue from COPD patients a concomitant up-regulation of collagenases 1 and 2 (i.e. MMP-1 and MMP-8) and gelatinases A and B (i.e. MMP-2 and MMP-9) has been reported by Segura-Valdez et al. (2000) .
Numerous MMPs genes are located in one cluster region of chromosome 11q21-23; genes coding for other MMPs are scattered over chromosomes 1, 8, 12, 14, 16, 20 and 22 (Parks & Shapiro 2001) . Several polymorphisms potentially affecting gene expression have been described in promoter regions of MMPs genes (Table 1) . In a recent Japanese study the importance of MMP-9 gene -1562C/T promoter polymorphism in the development of pulmonary emphysema in Japanese smokers was suggested (Minematsu et al. 2001 ) and this was reported again in another recent Japanese study (Ito et al. 2005) . In Caucasians, Joos et al. (2002a) showed that the MMP-1 gene G-1607GG promoter polymorphism and the MMP-12 gene Asn357Ser polymorphism in the coding region were associated with the rate of decline in lung function in continuing smokers. However, no association was found between the MMP-9 -1562C/T gene promoter polymorphism and lung function decline in this study (Joos et al. 2002a) , in contrast with the finding in a Chinese population (Zhou et al. 2004) (Table 1) . A disintegrin and metalloprotease 33 (ADAM-33) gene, previously identified as a susceptibility gene for asthma (Werner et al. 2004) , contains several SNPs that were shown to be associated with accelerated lung function decline in general population (Van Diemen et al. 2005) . In addition, the prevalence of SNPs F+1 (G A), S 1 (Val Iso), S 2 (G C) and T 2 (Pro Ser) was significantly higher in subjects with COPD compared to matched healthy control subjects in the same study (Table 1 ) (Van Diemen et al. 2005) .
Tissue inhibitors of metalloproteinases (TIMPs) counteract the proteolytic activity of MMPs (Parks & Shapiro 2001) . Gene polymorphisms that downregulate the TIMPs activity may result in the increased degradation of the lung matrix by MMPs. In this regard, polymorphisms of the TIMP-2 gene were investigated (Table 1) . The -418G/C gene polymorphism in the promoter region and the +853G/A polymorphism in exon 3 of the TIMP-2 gene may be associated with the development of COPD, decreasing the transcription and stability of the messenger RNA (Hirano et al. 2001) . In another recent study in an Egyptian population, the +853G/A polymorphism but not the -418G/C polymorphism was shown to play a significant role in the susceptibility to COPD (Hegab et al. 2005b) .
Taken together, certain polymorphisms within the MMPs (MMP-9 -1562C/T in emphysema) and TIMPs (TIMP-2 +853G/A) genes have been repeatedly associated with COPD-related phenotypes, while other associations (MMP-9 -1562C/T related to lung function, TIMP-2 -418G/C) were not replicated in different populations and with different phenotypes under study (Table 1).
Gene polymorphisms of antioxidants in relation to COPD
Reactive oxygen species have important consequences for the pathogenesis of COPD, such as oxidative inactivation of antiproteinases, alveolar epithelial injury, increased sequestration of neutrophils, and gene expression of proinflammatory mediators (Kluchová & Tkáčová 2006) . The source of oxidants is two-fold: exogenous compounds from the tobacco smoke, and endogenous -largely neutrophil-derived reactive oxygen species possessing the ability to interact with the structure and function of biomolecules (MacNee 2005) . The action of oxidants is counterbalanced by endogenous antioxidant defence mechanisms. First-pass metabolism of harmful cigarette smoke-derived compounds in the lungs is an important protective mechanism against oxidative stress. Polymorphisms in the genes for cytochrome P450 1A1 (CYP1A1), microsomal epoxide hydrolase (mEPHX) or glutathione Stransferases (GSTs), enzymes involved in this protective process, may influence individual susceptibility to the development of COPD (Gaspar et al. 2004; Teramoto et al. 2005) . Heme oxidase-1 (HMOX-1) with its final product bilirubin, a non-enzymatic scavenger, represents another mechanism capable to reduce the load of oxidants in the lungs (Maestrelli et al. 2001) .
Microsomal epoxide hydrolase
This is an enzyme that metabolizes xenobiotic reactive epoxide intermediates. The mEPHX has dual functions; it catalyzes the hydrolytic conversion of arene-, alkene-, and aliphatic epoxides to less reactive and more watersoluble dihydrodiols, but, on the other hand, it also activates polycyclic aromatic hydrocarbons present in cigarette smoke into more carcinogenic forms (Gelboin 1980) . Hence, although mEPHX metabolizes some tobacco carcinogens into highly mutagenic diol epoxides (Pastorelli et al. 1998) , it is considered as mainly a protective enzyme involved in the defence against oxidative damage from a number of environmental xenobiotic substances .
The human mEPHX gene is localised to the chromosome 1q and consists of 9 exons. Among 11 SNPs in the coding region of the mEPHX reported, functional analyses performed on two non-synonymous polymorphisms in exon 3 (Tyr113→His) and exon 4 (His139→Arg) yielded associations with alterations in mEPHX activity (Hassett et al. 1994) . Two common aberrant alleles can be detected, which confer slow and fast enzyme activity: an exon 3 T to C mutation changes Tyr 113 residue to His, thus reducing the enzyme activity by ≥ 50% (slow allele), and an A to G transition in exon 4 changes His 139 residue to Arg resulting in expression of mEPHX with an activity increased by ≥ 25% (fast allele). The distance between exon 3 and exon 4 is 6696 base pairs (Hassett et al. 1994) . Since the mEPHX is active also in human lung tissue (Omiecinski et al. 1993) , mEPHX polymorphisms may confer risks for lung diseases.
Results from previous epidemiological studies that investigated the association between mEPHX polymorphisms and risk for COPD are inconsistent ( Table 2) . Most of the studies reported significant associations between low mEPHX activity genotypes and the risk for COPD Sandford et al. 2001; Rodriguez et al. 2002; Xiao et al. 2003; Cheng et al. 2004; Park et al. 2005 ). In the study by Sandford et al. (2001) , a combination of a family history of COPD together with a homozygosity for the His 113 /His 139 haplotype in the mEPHX gene was associated with rapid decline of lung function. Rodriguez et al. (2002) found a significantly higher proportion of individuals homozygous for mutant exon 3 among COPD patients than control subjects whereas Xiao et al. (2003) reported similar results for mEPHX exon 3 heterozygotes. In addition, a comparison of patients with severe COPD to those with mild-to-moderate disease revealed that the frequency of the homozygous His113His mEPHX exon 3 variant was significantly higher in severe COPD (Cheng et al. 2004 ). In the study by Park et al. (2005) , a significantly increased risk for COPD was observed for subjects with the mEPHX (His113His) genotypes. On the other hand, two studies failed to demonstrate an association between low activity variant of mEPHX and COPD Zhang et al. 2002) .
Glutathione S-transferases
GSTs are members of a superfamily of at least 20 isoenzymes involved in the conjugation of a wide range of electrophilic substances with glutathione, thereby facilitating detoxication and further metabolism and excretion. GSTs activity can be either cytosolic or cell membrane-bound. Cytosolic GSTs are separated into the following 8 classes: α, µ (GSTM), θ (GSTT), π (GSTP), ζ, σ, κ and χ .
Sixteen GSTs genes coding cytosolic GSTs have been described. Further six genes code for cell mem-24 E. Slabá et al. brane GSTs (Hayes & Strange 2000) . Polymorphisms of GSTP1, GSTM1 and GSTT1 were studied extensively in patients with COPD and with lung cancer (Table 2) . The GSTM1, GSTT1 and GSTP1 genes are located on chromosomes 1p13.3, 22q11.2 and 11q13, respectively . GSTM1 is involved in degradation of active metabolites of polycyclic aromatic hydrocarbons (Ketterer et al. 1992) , whereas GSTT1 participates in detoxication of small hydrocarbons of tobacco smoke (such as monohalomethanes and ethylene oxide) (Guengerich et al. 1995) . The GSTP1 enzyme accounts for more than 90% of all GST activity and metabolizes products of DNA oxidation . The µ class of GSTs is coded by 5 genes: GSTM1, GSTM2, GSTM3, GSTM4, and GSTM5 (Xu et al. 1998) . GSTM1 has three different alleles: GSTM1*0 (homozygous for deletion, no expression of the protein), GSTM1*A and GSTM1*B differing in one nucleotide within exon 7, with frequency of the GSTM1*0 allele in general population of 40-50% (Hayes & Strange 2000) . This deletion allele was demonstrated to occur in a higher frequency in patients with emphysema and lung cancer . Cheng et al. (2004) demonstrated that the GSTM1 null genotype is a risk factor for developing COPD in a Taiwanese population (Table 2) . A different study in a Caucasian population indicated that the presence of at least one active allele in the GSTM1 locus had a protective effect against the development of COPD in smokers with non-small-cell lung cancer (Tkacova et al. 2004) .
The θ class of GSTs is represented by two genes: GSTT1 and GSTT2 (Xu et al. 1998) . The GSTT1*0 mutant has also been suggested as a risk factor for human lung disease (Cheng et al. 2004 ). In Caucasians, homozygotes for the null allele are present with 20% frequency (Hayes & Strange 2000) . Taioli et al. (2003) found a marginally significant association (OR = 1.2, 95% CI: 1.0-1.6) between lung cancer and GSTT1 null genotype. Studies in COPD subjects (Table 2) failed to show any association between COPD and polymorphisms of the GSTT1 gene (Yim et al. 2000; Cheng et al. 2004) .
The GSTP1 gene is expressed more abundantly in respiratory tissues compared to other types of GSTs (Cheng et al. 2004 ). The GSTP1 gene contains two previously reported polymorphisms; an A→G transition at nucleotide +313 in exon 5, which leads to the Ile105→Val amino acid substitution, and a C→T transition at nucleotide +341 in exon 6, which leads to the Ala114→Val substitution . Individuals with the Val105 allele have higher risk of developing lung cancer than those with the Ile105 allele (Ryberg et al. 1997) . A Japanese study demonstrated an increased prevalence of the Ile105Ile genotype in patients with COPD (Ishii et al. 1999 ). In addition, He et al. (2002) reported that a combination of a family history of COPD with GSTP1 Ile105Ile genotype was associated with a rapid decline of lung function. In contrast, however, Cheng et al. (2004) did not find any association between the GSTP1 genotype and COPD (Table 2).
Cytochrome P450 1A1
It metabolizes xenobiotic compounds, thus enabling their excretion. This enzyme is involved in the activation of benzopyrenes and other polycyclic aromatic hydrocarbons and amines; all of them major classes of tobacco smoke-derived pro-carcinogens (Yin et al. 2001) . A mutation in exon 7 of CYP1A1 gene causes an amino acid substitution (Ile462→Val) which results in increased CYP1A1 activity in vivo (Cosma et al. 1993 ). The high-activity allele (Val462) was associated with susceptibility to centriacinar emphysema (OR = 2.45, CI: 1.06-5.67, p = 0.035) in patients who had lung cancer (Cantlay et al. 1995) .
The m1 polymorphism in the 3'-noncoding region (3'UTR) of the CYP1A1 gene arises from T→C transition, thus the m1 allele bears a MspI cleavage site, in contrast to the wild-type variant. The CYP1A1 m1 polymorphism has been associated with increased levels of activated intermediate metabolites due to alterations in transcript half-life (Landi et al. 1994) . In patients with lung cancer, individuals who presented the GSTT1 null genotype and CYP1A1*1A/*2A heterozygous genotype of m1 polymorphism had an increased risk of COPD than individuals without these genotypes (OR= 3.7, CI: 1.1-14.6, p = 0.04) (Gaspar et al. 2004 ).
Heme oxygenase-1 Heme oxygenase-1 (HMOX-1) is a key enzyme in heme catabolism that catalyzes the oxidative cleavage of heme, resulting in the release of carbon monoxide, iron, and biliverdin. Biliverdin is subsequently reduced to bilirubin by biliverdin reductase. Bilirubin acts as a non-enzymatic scavenger involved in the antioxidant defence and is present in higher concentrations in the lungs of smokers than non-smokers, suggesting up-regulation in these circumstances (Maestrelli et al. 2001) .
The HMOX-1 gene (GT)n dinucleotide repeat in the 5'-flanking region shows a variable length polymorphism, and there is evidence that it modulates the level of gene transcription under thermal stress (Okinaga et al. 1996) . Two human studies showed a link between this polymorphism and COPD: a Japanese case-control study demonstrated that patients with 30 or more GT repeats in microsatellite region were more likely to have emphysema diagnosed by CT scan (OR = 2.4, 95% CI: 1.3-4.1) (Yamada et al. 2000) . A larger study of 749 subjects in France showed that 33 or more GT repeats were associated with greater airflow obstruction and more rapid decline of lung function in heavy smokers (Guenegou et al. 2006) . In contrast, no association between HMOX-1 (GT)n alleles and the rate of decline in lung function was observed among the participants of the Lung Health Study .
Gene polymorphisms of inflammatory mediators in relation to COPD
Abnormal inflammatory response of the lungs to noxious substances is a key feature of COPD (Celli et al. 2004; Wouters 2005) . Various inflammatory mediators, such as TNF-α, IL-8 (Wouters 2005) or vitamin Dbinding protein (VDBP) (Horne et al. 1990 ) were implicated in cell recruitment and differentiation, apoptosis, signalling and further up-regulation of inflammation, stimulation of the production of endogenous oxidants, and worsening the pre-existing proteinaseantiproteinase imbalance.
Tumor necrosis factors TNF-α and lymphotoxin (TNF-β) are proinflammatory cytokines that stimulate the release of neutrophils from the bone marrow, and promote subsequent neutrophil activation. Since neutrophils are the hallmark of the inflammatory process in COPD, the family of TNF-α cytokines are intimately related to the pathogenesis of this disorder (Wouters 2005) .
The TNF family of genes includes: (a) the TNF-α gene; (b) the Lt-α gene encoding lymphotoxin-α (often referred to as TNF-β); and (c) two genes of TNF receptors 1 and 2 (TNFR1 and TNFR2, also referred to as p55 TNFR and p75 TNFR). TNFR1 and TNFR2 are type-I membrane ligands on the cell surface for both TNF-α and Lt-α. Both TNF receptors are involved in mediating numerous TNF-α and Lt-α effector functions (Ferrarotti et al. 2003) .
The first known gene polymorphism in this family was an SNP G/A at the position -308 in the TNF-α gene promoter region (Wilson et al. 1992) . The presence of the less common type 2 allele was associated with higher gene expression in vitro. Carriage of the TNF2 allele also conferred a higher risk to the development of chronic bronchitis in a Taiwanese population (Huang et al. 1997 ). In the study by Sakao et al. (2001) , a significant relationship between the TNF1/2 allele frequency and the presence of smoking-related COPD in Japanese was revealed. Sakao et al. (2002) subsequently assessed the extent of emphysematous changes in COPD patients using high-resolution CT scanning. Their results indicated that the TNF-α-308 allele 2 might be partly associated with the emphysematous phenotype (Sakao et al. 2002) . In contrast, associations between the TNF2 allele and COPD were not confirmed in other studies, neither in Caucasians (Higham et al. 2000; Patuzzo et al. 2000) , nor in a Japanese population (Ishii et al. 2000) (Table 3 ). There was no association between the TNF-α gene promoter genotype and the severity of airflow obstruction or the degree of emphysema in COPD (Higham et al. 2000) , neither this genotype played a significant role in bronchiectasis developing as a consequence of frequent respiratory tract infections in COPD patients (Patuzzo et al. 2000) . A study investigating the -308G/A polymorphism in the TNF-α gene, the LtαNcoI polymorphism in the Lt-α gene, the A/G polymorphism in the TNFR1 gene, and the M/R polymorphism in the TNFR2 gene, did not yield any association between these polymorphisms and a risk for COPD (Ferrarotti et al. 2003) . The uncertainty regarding the relationship between the TNF-308G/A polymorphism and TNF-α expression in vivo as well as the possibility of another TNF gene polymorphism of greater functional significance in COPD also need to be considered (Higham et al. 2000; Ferrarotti et al. 2003) .
Beside the -308G/A promoter polymorphism, several different biallelic polymorphisms in the TNF-α gene were described (Table 3) . Kucukaycan et al. (2002) reported that the +489G/A polymorphism within the first intron of the TNF-α gene was linked to COPD. Carriership of the minor allele was associated with en- hanced risk of the development of the disease, and the link was present particularly in a subgroup of patients without radiological signs of emphysema. However, genotyping for the polymorphisms at positions -376, -308, and -238 showed no similar associations . More recent papers on the -308G/A TNF-α gene promoter polymorphism did not report any significant link to COPD neither in a German, a Thai, nor a Han Chinese population (Chierakul et al. 2005; Jiang et al. 2005; Seifart et al. 2005 ) (Table 3).
Interleukines
The IL-1 complex consists of two different proinflammatory cytokines, IL-1α and IL-1β, and a naturally occurring anti-inflammatory agent, the IL-1 receptor antagonist (IL-1RN). IL-1RN is a 16-18 kDa protein that binds to the IL-1 receptor with the same affinity as IL-1 but does not possess agonist activity and therefore acts as a competitive inhibitor of IL-1 (Joos et al. 2002b ). IL-1 and its antagonist may influence the rate of decline in lung function because of the effects of IL-1 on neutrophil function and chemotaxis. IL-1 stimulates the synthesis of IL-8 which is a potent chemotactic agent for neutrophils, and it also induces release of neutrophil elastase (Joos et al. 2001) . The genes of the IL-1 complex are located on the long arm of chromosome 2 (Steinkasserer et al. 1992 ). The IL1B gene contains an SNP in the promoter region (C-511T) and the IL1RN gene contains a pentaallelic tandem-repeat polymorphic site in intron 2. None of the genotypes alone were associated with the susceptibility to COPD, nor with the rate of decline of lung function in smokers (Ishii et al. 2000) . However, the distribution of IL1B/IL1RN haplotypes differed in smokers with a rapid decline in lung function from non-decliners (Joos et al. 2001) . Interestingly, a recent study by Broekhuizen et al. (2005) suggested that the C-511T polymorphism of the IL1B gene might be linked to pulmonary cachexia, a systemic complication of COPD that relates to the magnitude of inflammatory response. Another recent study indicated that a different haplotype within the IL1B gene (IL1B T-31C / IL1B C-3954T) may be involved in the pathogenesis of COPD (Hegab et al. 2005a ). The Boston Early-Onset COPD Study identified chromosomes 2 and 12 as having linkage to qualitative and quantitative COPD-related phenotypes (Silverman et al. 2002a,b) . Association studies considering the candidate genes within this region yielded significant associations of the polymorphisms of genes encoding IL-8 receptor A and B (IL8RA, CXCR-1 and IL8RB, CXCR-2) and lung function in the relatives of patients with severe COPD (Demeo et al. 2004b) . IL-8 is a potent proinflammatory cytokine, which acts via the IL-8RA and IL-8RB receptors, leading to activation and migration of leukocytes. Two SNPs in the IL8RA and one in the IL8RB gene were associated with mild airflow obstruction in subjects at risk for COPD, and another polymorphism in the IL8RA gene was linked to postbronchodilator forced expiratory volume in the first second (Demeo et al. 2004b ). The frequencies of selected IL8RA alleles were significantly increased in patients with COPD and in children with asthma compared to healthy controls in another recent study (Stemmler et al. 2005) . Therefore, these polymorphisms may play a role in the pathogenesis of COPD and asthma.
A promoter polymorphism (C-1055T) was identified within the IL-13 gene. The TT homozygote genotype increased the risk to develop COPD in smokers and in subjects with family history of COPD in a Chinese population (Jiang et al. 2005 ). An increased frequency of the -1055 T allele was reported in COPD patients compared to healthy controls and to smokers with normal lung function ( Van der Pouw Kraan et al. 2002) . These results could implicate a functional role for the IL-13 promoter polymorphism in the enhanced risk to develop COPD. Moreover, T allele frequencies similar to those in COPD patients were observed in adult patients with bronchial asthmas, demonstrating a potential common candidate gene for the pathogenesis of both obstructive airway diseases (Meyers et al. 2004 ).
Vitamin D-binding protein Vitamin D-binding protein (VDBP), also known as Gc globulin, is a 55 kDa protein secreted by the liver which is able to bind vitamin D, extracellular actin and endotoxin. VDBP is known to undergo conversion to a potent macrophage-activating factor (Yamamoto et al. 1991) . Thus, besides its vitamin D-binding function, VDBP enhances the neutrophil chemotactic properties of C5 derived peptides (Kew & Webster 1988 ).
There are three major isoforms of this protein (1S, 1F and 2) resulting from two common substitutions in exon 11 of the gene. The allele 2 has been found to be protective against development of airflow limitation in Caucasian subjects (Schelenberg et al. 1998; Horne et al. 1990 ). In contrast, 1F homozygous genotype conferred an increased risk for COPD (Horne et al. 1990 ). Recently, 1F allele has been linked to an increased risk of developing airflow obstruction, emphysema and a rapid decline of FEV 1 also in Japanese subjects (Ito et al. 2004 ). Nevertheless, the study of Sandford et al. (2001) failed to demonstrate an association between this genotype and accelerated decline of lung function ).
Transforming growth factor-β1
Transforming growth factor-β1 (TGFβ1) is an important anti-inflammatory and profibrotic chemokine. In vitro, TGFβ1 regulates immune responses, growth and differentiation of cells, tissue repair, and extracellular matrix production (Blobe et al. 2000) . Studies in animal models strongly suggest that abnormalities in the activation and signaling of TGFβ1 are important in the pathogenesis of emphysema (Morris et al. 2003) .
TGFβ1 gene is located on chromosome 19q, a region of the genome linked to COPD-related phenotypes (Celedon et al. 2004 ). Wu et al. (2004) demonstrated an association between the Leu10Pro polymorphism (rs1982073) and COPD. The Pro10 allele was associated with an increased production of TGFβ1 which raises the possibility that TGFβ1 has a protective role in COPD. Celedon et al. (2004) showed that the rs2241712 promoter polymorphism was associated with COPD both in the family-based and in the case-control study. Two other polymorphisms, a promoter SNP C-509T (rs1800469) together with the Leu10Pro polymorphism were also associated with COPD susceptibility in this case-control study (Celedon et al. 2004; Wu et al. 2004 ). These associations were replicated for two latter functional polymorphisms by Hersh et al. (2006a) , who also showed correlations between the respective genotypes and the TGFβ1 expression in lung tissue from COPD patients.
Gene polymorphisms of β-2-adrenergic receptor in relation to COPD
Airway hyperresponsiveness is a known risk factor for the respiratory symptoms in patients with COPD. Previous studies were largely focused on the role of β-2-adrenergic receptor (ADRB2) and its gene polymorphisms (Joos et al. 2002b) .
ADRB2 is a G protein-coupled, seven-transmembrane-domain receptor that is widely distributed throughout the body and mediates the actions of catecholamines in various tissues and organs (Johnson 1998) . It has been implicated in a range of disease states, including respiratory disorders (Littlejohn et al. 2002) . ADRB2 expressed by bronchial smooth muscle cells acts to relax the contracted muscle, resulting in bronchodilation (Drysdale et al. 2000) . Therefore, ADRB2 is a target for β-2-agonist drugs used as bronchodilators, and for β-blocking agents (Liggett 2000) .
The ADRB2 is encoded by a single gene that lacks introns, and is located on chromosome 5q31-32 (Kobilka et al. 1987) . ADRB2 is polymorphic, with numerous SNPs described throughout the gene and its flanking regions (Drysdale et al. 2000) . Several SNPs are located in the 5'-flanking region of the gene, and some of these may affect promoter activity or regulation of the gene. Four of the known common polymorphisms alter amino acid residues within the mature receptor, and one alters an amino acid residue in the 5'-ADRB2 upstream peptide that is involved in translational regulation of the ADRB2. Several SNPs do not alter the coding sequence, and it remains to be recognised what effect, if any, these may have on gene function and expression (Littlejohn et al. 2002) .
Those of ADRB2 polymorphisms that alter the receptor function are present at nucleotide positions 46, 79, and 491. These polymorphisms result into amino acid substitutions Arg16→Gly, Gln27→Glu, and Thr164→Ile, respectively (Ho et al. 2001) . The polymorphisms at amino acid positions 16 and 27 have been studied extensively from a pharmacogenetic perspective (Joos et al. 2002b ), but only few previous studies assessed their role in the susceptibility to COPD (Ho et al. 2001; Joos et al. 2003; Brogger et al. 2006) . In a Chinese population, the polymorphism of Gly16 was reported to increase the patient's susceptibility to the development of COPD, and the Gln27 ADRB2 polymorphism was associated with the severity of COPD (Ho et al. 2001) . Joos et al. (2003) found a significant protective role for heterozygosity at position 27 against a rapid decline in lung function in smokers. Nevertheless, no association of ADRB2 polymorphisms and risk of COPD were reported in that study (Joos et al. 2003) and a meta-analysis of previous studies by Brogger et al. (2006) in smokers and former smokers. Drysdale et al. (2000) described the haplotype structure of human ADRB2 by characterizing 13 SNPs 28 E. Slabá et al.
followed by determining possible haplotypes through cloning in bacterial plasmids and a DNA sequence analysis. This study established the existence of 12 distinct haplotypes, although only four of these accounted for the majority of haplotypes in subjects across different ethnic backgrounds (Drysdale et al. 2000) . Considering the inconsistent data on the role of SNPs of the ADRB2 in patients with COPD (Ho et al. 2001; Joos et al. 2003; Brogger et al. 2006) , it is surprising that little effort was put into unravelling the role of ADRB2 haplotypes on baseline pulmonary function and/or bronchodilator response in COPD patients. Hegab et al. (2004) examined the distributions of the haplotypes combined from SNPs in the IL-4 gene and the SNP at amino acid position 27 of the ADRB2 gene in Japanese and Egyptian populations of COPD patients and found significant differences compared to control groups. To date, no other study looking at possible role of ADRB2 haplotypes in patients diagnosed with COPD has been published.
Gene polymorphisms associated with pulmonary hypertension in COPD
Pulmonary hypertension is frequently observed in patients with advanced COPD as a consequence of chronic alveolar hypoxia. However, since oxygen supplementation failed to restore normal pulmonary artery pressures, various vasoactive mediators have been implicated in sustained pulmonary vasoconstriction and vascular remodelling (Barbera et al. 2003) .
Serotonin transporter
Serotonin transporter (SERT) expressed on cell membranes in brain and in peripheral tissues is responsible for the active transport of serotonin into neurons, plateles, and other cells. SERT mediates rapid removal and recycling of released serotonin following neuronal stimulation. Thus, it has a critical role in the homeostatic regulation of the magnitude, duration, and spatial distribution of signals reaching serotonin receptors (Murphy et al. 2004) .
Human SERT gene spans 37.8 kb on chromosome 17q11.2, and is composed of fourteen exons encoding a protein of 630 amino acid residues (Lesch et al. 1994 ). In addition to several regulatory domains controlling selective expression in serotoninergic neurons, transcriptional activity of human SERT is modulated by a repetitive element of varying length in the 5'-flanking region located ∼1.4 kb upstream of the transcription start site, termed the SERT gene-linked polymorphic region (5HTTLPR) (Murphy et al. 2004 ). 5HTTLPR alleles are most commonly composed of either fourteen ("short" or "S" allele) or sixteen ("long" or "L" allele) repeated elements (each of 20-23 bp), although alleles with more repeat elements ("superlong", "XL" and "XXL" with up to twenty repeats) occasionally occur (Lesch & Moessner 1998) .
Serotonin is a potent inducer of smooth muscle cell proliferation in lung vessels (Eddahibi et al. 2001) . Individuals with spontaneous primary pulmonary hypertension more frequently have the 5HTTLPR LL genotype. Unlike primarily hypertensive patients, hypoxic patients with COPD do not differ from controls in 5HT-TLPR genotype frequencies; however, the LL variant of 5 HTTLPR in COPD patients, who have higher SERT expression in pulmonary artery cells, was associated with significantly more severe pulmonary hypertension compared to LS or SS patients (Eddahibi et al. 2003) , what is in accordance with findings in rodent models (Eddahibi et al. 2000) .
Angiotensin-converting enzyme Angiotensin-converting enzyme (ACE) is a carboxypeptidase that catalyses conversion of angiotensin I to angiotensin II which is the major active peptide of the renin-angiotensin system, one of the main systems regulating blood pressure and fluid-electrolyte balance (O'Donnell et al. 1998) . In animal studies, components of the renin-angiotensin system were shown to play an important role in both hypoxia-induced vasoconstriction and pulmonary vascular remodelling which are the mechanisms involved in sustained increases in pulmonary artery pressures (Morrell et al. 1995) .
Carriers of the D allele have higher serum and tissue ACE activities (Danser et al. 1995) . The vast majority of the total activity of ACE in the body is found in lung tissue and increases further after stimulation by chronic hypoxia (Kanazawa et al. 2002 ). An insertion/deletion (I/D) polymorphism at intron 16 of the ACE gene has been associated with increased risk of systemic arterial hypertension (O'Donnell et al. 1998) , atherosclerosis (Tkac et al. 2003) and also with resting pulmonary artery pressure in Caucasian patients with COPD (Tkacova et al. 2005) . Previously, a Japanese study suggested that in patients with COPD the ACE DD genotype might be associated with pulmonary artery pressure increases during exercise (Kanazawa et al. 2000) .
Future perspectives of association studies and linkage analyses in COPD
Although case-control genetic association studies have been widely used in the study of genetics of COPD in the general population, they have been criticized because of a lack of replication (Hirschhorn & Altshuler 2002; Hersh et al. 2005) . Often the first published study reports on a significant association between a candidate gene polymorphism and a disease of interest, nevertheless, subsequent studies fail to confirm the reported association (Ioannidis et al. 2001; Hersh et al. 2005) .
Results of association studies may differ across different populations due to a number of factors: variations in the frequency of SNPs in different populations, the modulating effects of other SNPs or mutations within individuals, variation in the penetrance of the effects of an SNP due to environmental factors such as age and other exposures (Tebbutt et al. 2007 ), multiple statistical testing (testing many genetic variants and/or many phenotypes and not properly adjusting the level of statistical significance), small sample sizes, and random error (Silverman & Palmer 2000; Hersh et al. 2005) .
In an effort to determine whether some of the previously reported significant associations exists between various genetic polymorphisms and susceptibility to COPD, Hersh et al. (2005) performed the test of replication. A total of twenty-nine polymorphisms in twelve candidate genes for COPD were genotyped in a family-based COPD study as well as in a case-control COPD study. Although some evidence for replication was found for surfactant protein B (SFTB) and HMOX-1, none of the previously published COPD genetic associations was convincingly replicated across both study designs. Nevertheless, in a more recent study using the test-replication approach, Hersh et al. (2006a) identified four genes -mEPHX, SFTB, latent transforming growth factor-β-binding protein-4 gene(LTBP4), and TGFB1 gene to be associated with COPD-related phenotypes. Moreover, in the study on a total of seventyseven polymorphisms in twenty candidate genes, polymorphisms in GSTP1 and mEPHX were associated with apical-predominant emphysema in COPD (DeMeo et al. 2007 ). Importantly, the association of GSTP1 Ile105Val polymorphism with emphysema distribution was confirmed also using the test-replication approach (DeMeo et al. 2007) .
Genetic linkage studies are powerful for the study of single gene disorders, but they have limited power in complex genetic disorders like COPD when many genes are likely to be involved, and there is no established model for the inheritance of the given disease (Cookson 2006) . To date, the only published genetic linkage analyses in COPD have been performed in the Boston Early-Onset COPD Study. Genome-wide linkage analysis was performed in 585 members of 72 extended pedigrees with 377 short tandem repeat markers. Both qualitative (airflow obstruction and chronic bronchitis) and quantitative prebronchodilator and postbronchodilator COPD-related phenotypes were analyzed. Seven regions of at least suggestive linkage to spirometric phenotypes have been identified on chromosomes 1p (two regions), 2q, 8p, 12q, 17q, and 19q (Silverman et al. 2002a,b; Palmer et al. 2003; DeMeo et al. 2004a) .
Following the identification of these regions of linkage, positional candidate genes can be tested for associations to COPD-related phenotypes and systematic screening across regions of linkage can be performed in the near future. As an example, based on demonstrated significant evidence of linkage to chromosome 8p for FEV 1 , Hersh et al. (2006b) sought to map the linkage peak and to test variants in two candidate genes, defensin β-1, and macrophage scavenger receptor-1 for association with COPD and related traits. Indeed, a coding variant (Pro275Ala) in the latter one was significantly associated with two qualitative airflow obstruction traits (Hersh et al. 2006b ).
In conclusion, based on the inconsistent results of COPD genetic association studies, no COPD genetic determinants (other than severe α 1 -antitrypsin deficiency) have been identified with certainty. Nonetheless, it is quite possible that at least some of the inconsistently associated candidate genes will ultimately prove to be valid COPD susceptibility genes. Moreover, the recent genetic linkage studies have provided an array of positional candidate genes for future association studies. Further efforts at replication of significant genetic associations using large sample sizes and demonstration of functional significance of associated genetic variants using animal models and/or in vitro systems will be required to confirm novel genetic determinants of COPD susceptibility.
